Consensus treatment recommendations for late-onset Pompe disease - Wikidata - awgldk - TriplyDB

Consensus treatment recommendations for late-onset Pompe disease

Consensus treatment recommendations for late-onset Pompe disease

http://www.wikidata.org/entity/Q34634354

about

Review and evaluation of the methodological quality of the existing guidelines and recommendations for inherited neurometabolic disorders Practical Recommendations for Diagnosis and Management of Respiratory Muscle Weakness in Late-Onset Pompe Disease A broader view: microbial enzymes and their relevance in industries, medicine, and beyond.Muscle imaging data in late-onset Pompe disease reveal a correlation between the pre-existing degree of lipomatous muscle alterations and the efficacy of long-term enzyme replacement therapy.Respiratory muscle training with enzyme replacement therapy improves muscle strength in late - onset Pompe disease.Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review.Pompe disease: literature review and case series Diagnosis and treatment of late-onset Pompe disease in the Middle East and North Africa region: consensus recommendations from an expert group Muscle MRI Findings in Childhood/Adult Onset Pompe Disease Correlate with Muscle Function.Familial Pompe Disease Therapeutic advances in the management of Pompe disease and other metabolic myopathies Sleep-Disordered Breathing and Effects of Noninvasive Ventilation in Patients with Late-Onset Pompe Disease.Exercise in neuromuscular disease.Ethical considerations of population screening for late-onset genetic disease.Guidelines for the diagnosis, treatment and clinical monitoring of patients with juvenile and adult Pompe disease.Pompe Disease: Diagnosis and Management. Evidence-Based Guidelines from a Canadian Expert Panel.Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis.European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience.Late-onset pompe disease in Iran: A clinical and genetic report.Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment.Clinical Analysis of Algerian Patients with Pompe Disease.The influence of a polymorphism in the gene encoding angiotensin converting enzyme (ACE) on treatment outcomes in late-onset Pompe patients receiving alglucosidase alfa Early is better? A new algorithm for early diagnosis in late onset Pompe disease (LOPD).[Diagnosis and therapy of late onset Pompe disease].Low-frequency enzyme replacement therapy in late-onset Pompe disease.Current and Future Treatments for Lysosomal Storage Disorders.The humanistic burden of Pompe disease: are there still unmet needs? A systematic review.Screening for late-onset Pompe disease in western Denmark.Respiratory manifestations in late-onset Pompe disease: a case series conducted in Brazil.Structural and functional cardiac analyses using modern and sensitive myocardial techniques in adult Pompe disease.Swiss national guideline for reimbursement of enzyme replacement therapy in late-onset Pompe disease.Postoperative acute respiratory failure caused by adult-onset Pompe disease.Fibromyalgia-like symptoms associated with irritable bowel syndrome: A challenging diagnosis of late-onset Pompe disease.Acute respiratory failure as presentation of late-onset Pompe disease complicating the diagnostic process as a labyrinth: a case report Orthopedic management of patients with Pompe disease: a retrospective case series of 8 patients

P2860

Q26771677-BF802139-19BE-4B79-9A94-4F7606F58046 Q28067387-EEFA1B9D-6CDA-489B-8B8D-3890EDDBCAAD Q30393023-53711C9B-9F6C-427C-A3A0-4C1043C39B6A Q31052050-D9957F32-5B03-4D7A-A412-810004C53486 Q33800051-39A30EA8-B96B-442B-8FDC-0FD9C8FC69D0 Q34641771-BDDEB055-0721-44F3-886E-D0A01E6D8C2F Q35029971-63F18A24-2F36-4001-8E1D-F33ABA6BB139 Q35809528-409FFE68-0178-43FA-8287-9DA4A528287D Q36154874-C82833A6-6DA7-47CD-8AFC-896708D5A4FF Q36264496-CCB25489-0CC9-451C-B3FE-9018491A406C Q37127561-D986CC02-CB58-4981-B9EF-FB0377D7D817 Q37501141-272BEA7D-A596-4C93-90A0-938A0C347657 Q38108541-E56D93AD-0087-46E9-9A09-52CAB067A7C6 Q38354133-FE1A9917-905E-41FF-B795-548FA31A2874 Q38675468-13D4EBD4-F565-4FEC-91A1-920417FCF4B1 Q38800985-C6177694-BB1D-4D17-9BA6-8060B2A8905F Q38884347-2FB08503-FD38-40A6-953D-B6247214E5C2 Q39287288-F35BB06C-999E-4707-B1F0-67FD5A506A35 Q39370287-245CFB04-2EEE-4E05-88F0-9C7F69DF394C Q41448556-BE2FCE4D-F545-48D3-8F91-9E5EB49BBA27 Q42126616-1522AFE5-D0A3-4D48-BB55-E270B3F0A87E Q42403394-4B69B5C7-9BCB-4561-BEFF-305313E9B331 Q42787786-7BB38BD9-360E-47B1-80EE-9110BFC0518B Q44767256-58B68947-5922-443F-9DB8-B892029B0DCE Q45177347-1D60AFF5-B314-46CC-9443-41D8D1B44604 Q45873942-41B6089E-A48C-4A9B-A7BC-4FA55A7079FC Q46086672-50AE4873-8716-4D82-A45F-91A3489E398E Q47290108-3E0118C5-1FFC-4150-9A55-FB3D068AD9C5 Q47927846-43A1DEC5-5F60-45E4-998C-D019AF4FDCB2 Q48681869-7BBA72F1-AC4D-4BC0-82A4-4BAA3C97779D Q51236198-328F80F1-40D8-46BD-A3E3-AD01946B8624 Q51504548-437F8FD3-7C52-44E7-BD49-7D60BE5B93F3 Q51656691-55C0EDA7-16B2-4A1E-BB6C-7F67C89577E3 Q57193578-C692AD21-6A59-40FA-B077-73A8C57C2EA7 Q59101371-2BC1D618-8ADC-48D4-AF0F-E10582B512A1

P2860

Consensus treatment recommendations for late-onset Pompe disease

http://www.wikidata.org/entity/Q34634354

description

2011 nî lūn-bûn

@nan

2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Consensus treatment recommendations for late-onset Pompe disease

@ast

Consensus treatment recommendations for late-onset Pompe disease

@en

Consensus treatment recommendations for late-onset Pompe disease

@nl

type

label

Consensus treatment recommendations for late-onset Pompe disease

@ast

Consensus treatment recommendations for late-onset Pompe disease

@en

Consensus treatment recommendations for late-onset Pompe disease

@nl

prefLabel

Consensus treatment recommendations for late-onset Pompe disease

@ast

Consensus treatment recommendations for late-onset Pompe disease

@en

Consensus treatment recommendations for late-onset Pompe disease

@nl

P1433

Q34634354-C4746835-F046-432E-9568-B132F3F448F5

P1476

Q34634354-DE176AB4-906F-46D1-BBA2-E9D2E61450B7

P2093

Q34634354-01E74EDE-E274-4D5B-AC85-8DB47D90DB64

Q34634354-392AE06D-10AB-4C7C-89F7-62215209DB36

Q34634354-4C6E8FB4-F0D1-4A5F-9D71-D63C9E876630

Q34634354-5BC13E2B-C78E-4888-9DB7-12D587635C1F

Q34634354-F1379072-D66E-4A7D-A7FC-AE151A6B90C6

Q34634354-F2252D48-F4E8-40C2-A0A7-FAD4820775E8

Q34634354-F8E381C5-247E-48B1-9F74-E8A35742F4B2

P2860

Q34634354-011BD650-92A2-49DD-97BD-5F2F0CD6EB45

Q34634354-0282FDE6-606C-4147-9DD0-37874877113A

Q34634354-028B04AC-9237-4064-B592-92228A2A74DD

Q34634354-0BE187B5-A1B7-4F46-A69B-69559ECA0640

Q34634354-0F9EC4CA-6C83-4CC7-B6D7-08613FE9D94F

Q34634354-138043D8-4F32-4EEF-BDBC-5D76D8ACD29D

Q34634354-177382C7-63EE-4174-AB46-CFE44D5A3AAD

Q34634354-2774DB8B-DB01-4A83-88C8-73BED910F00B

Q34634354-2ACB1B3F-E93E-4EF2-ABC0-7988122DD4AF

Q34634354-2D7BBCB3-4FED-4C80-A087-A44A7BBA222F

P304

Q34634354-C6B7BF48-7358-49DD-8D11-95AD05A6B8A0

P31

Q34634354-48D1893F-4ED2-4818-986A-66ED9C08952A

P356

Q34634354-A8D7AA7C-B894-416B-B0A1-C8D5BD0FE2AB

P433

Q34634354-112A3A1F-8585-4C65-8A91-C76B92CAD427

P478

Q34634354-B5819F4A-92CB-40D6-A0B6-E1C1651A92C9

P50

Q34634354-EF36AFDE-08CD-47F1-A5EB-FF51849858C0

P577

Q34634354-39BE4046-4520-4396-B447-9FC09C095EA8

P5875

Q34634354-6BAC86A4-059C-49F5-B3A8-0E68A37A15BD

P698

Q34634354-FFE0331A-183C-418D-ACC6-669EDD0BE1F4

P932

Q34634354-2FDB668F-A423-4EC2-8D14-5125CAFD6A77

P356

P1433

Muscle and Nerve

P1476

Consensus treatment recommendations for late-onset Pompe disease

@en

P2093

AANEM Consensus Committee on Late-onset Pompe Disease

http://www.w3.org/2001/XMLSchema#string

Edward J Cupler

http://www.w3.org/2001/XMLSchema#string

Gil I Wolfe

http://www.w3.org/2001/XMLSchema#string

Jay J Han

http://www.w3.org/2001/XMLSchema#string

John T Kissel

http://www.w3.org/2001/XMLSchema#string

Richard J Barohn

http://www.w3.org/2001/XMLSchema#string

Robert T Leshner

http://www.w3.org/2001/XMLSchema#string

P2860

Side-alternating vibration training improves muscle performance in a patient with late-onset pompe disease

Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease

Functions of lysosomes

Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force

Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease.

Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease

Acid maltase deficiency and related myopathies.

Digital microfluidics: a future technology in the newborn screening laboratory?

Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling.

Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating.

P304

319-333

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MUS.22329

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

45

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth I. Berger

P577

2011-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51883769

http://www.w3.org/2001/XMLSchema#string

P698

22173792

http://www.w3.org/2001/XMLSchema#string

P932

3534745

http://www.w3.org/2001/XMLSchema#string